血管紧张素转换酶抑制剂治疗肾移植后继发性红细胞增多症  

Treatment of secondary erythromatosis following renal transplantation by ACE inhibitors

作　　者：杨志豪[1] 张钊[1] 姜永金[1] 

机构地区：[1]中日友好医院泌尿外科,北京100029

出　　处：《中华器官移植杂志》2001年第1期22-23,共2页Chinese Journal of Organ Transplantation

摘　　要：目的　观察血管紧张素转换酶抑制剂类药物对肾移植后继发性红细胞增多症的治疗效果及安全性。方法　对肾移植后临床诊断为红细胞增多症的 2 4例患者给予血管紧张素转换酶抑制剂类药物治疗 ,用药期间监测患者的血红蛋白、红细胞压积变化及其不良反应。结果　 2 4例中除 1例因低血压停药外 ,其余全部有效 ,起效时间为用药后 7～ 2 0d ;不良反应包括低血压伴头晕 3例 ,血红蛋白≤ 90 g/L 2例 ,肾功能损害 2例。 结论　血管紧张素转换酶抑制剂类药物对肾移植后的红细胞增多症有效 ;用药过程中需监测血、尿常规。Objective To observe the therapeutic effects and safety of angiotensin converting enzyme (ACE) inhibitors in the treatment of the secondary erythromatosis following renal transplantation.Methods Twenty four patients with erythromatosis following renal transplantation received the treatment with ACE inhibitors. During the administration of ACE inhibitors, the hemoglobin, hematocrit and the side effects were observed. Results All the patients were recovered except one who had to be stopped the treatment of ACE inhibitors because of the depressing of the blood pressure. The time of producing the effects was 7 20 days. The side effects included lower blood pressure accompanied by dizzy in 3 cases, anemia in 2 cases and damage to renal function in 2 cases. Conclusions ACE inhibitors were effective in the treatment of secondary erythromatosis following renal transplantation. It was important to monitor the hemogram and the renal function of the patients.

关 键 词：继发性红细胞增多症 血管紧张素转换酶抑制药 肾移植 治疗 

分 类 号：R699.2[医药卫生—泌尿科学] R555.1[医药卫生—外科学]